Yarrow Bioscience (YARW) Common Equity (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Common Equity came in at $24.6 million in Q1 2026, down 44.17% YoY from $44.1 million in Q1 2025, and down 11.27% on a QoQ basis from $27.8 million in Q4 2025.
Yarrow Bioscience (YARW) Common Equity (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Common Equity data on file, last reported at $24.6 million in Q1 2026.
- Quarterly Common Equity fell 44.17% year-over-year to $24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (down 44.17% YoY) and the FY2025 annual result came in at $27.8 million, down 46.69% from the prior year.
- Common Equity declined to $24.6 million in Q1 2026, from $27.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $88.7 million in Q4 2023 to a low of $11.5 million in Q3 2023.
- A 5-year average of $45.5 million and a median of $42.1 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity slumped 71.29% — and 2024, when it jumped 452.26%.
- Tracing YARW's Common Equity over 5 years: stood at $31.2 million in 2022, then surged by 184.39% to $88.7 million in 2023, then tumbled by 41.3% to $52.1 million in 2024, then slumped by 46.69% to $27.8 million in 2025, then retreated by 11.27% to $24.6 million in 2026.
- The last three Common Equity figures came in at $24.6 million (Q1 2026), $27.8 million (Q4 2025), and $38.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 22.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.06 Mn |
| Mar 31, 2026 | 24.64 Mn |
| Dec 31, 2025 | 27.77 Mn |
| Jun 30, 2025 | 38.88 Mn |
| Mar 31, 2025 | 44.13 Mn |
| Dec 31, 2024 | 52.09 Mn |
| Sep 30, 2024 | 63.54 Mn |
| Jun 30, 2024 | 74.87 Mn |
| Mar 31, 2024 | 83.37 Mn |
| Dec 31, 2023 | 88.74 Mn |
| Sep 30, 2023 | 11.51 Mn |
| Jun 30, 2023 | 17.27 Mn |
| Mar 31, 2023 | 26.43 Mn |
| Dec 31, 2022 | 31.20 Mn |
| Sep 30, 2022 | 40.07 Mn |
| Jun 30, 2022 | 48.36 Mn |
| Mar 31, 2022 | 55.73 Mn |
| Dec 31, 2021 | 48.64 Mn |
| Sep 30, 2021 | 58.89 Mn |
| Jun 30, 2021 | 74.89 Mn |